Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN II 10 versus LIPOSYN III 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN II 10 versus LIPOSYN III 10.
LIPOSYN II 10% vs LIPOSYN III 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential fatty acids (linoleic and linolenic) and calories for patients requiring parenteral nutrition; fatty acids are incorporated into cell membranes and serve as precursors for prostaglandins.
Liposyn III 10% is an intravenous fat emulsion that provides essential fatty acids (linoleic and linolenic acids) and a source of calories. The triglycerides are hydrolyzed by lipoprotein lipase to free fatty acids and glycerol, which are then utilized for energy production or stored. The emulsion particles are metabolized similarly to endogenous chylomicrons.
Intravenous infusion; maximum daily dose of 2.5 g/kg (25 mL/kg) provided as part of parenteral nutrition, typically administered over 12-24 hours.
Intravenous infusion: 500 mL to 1000 mL per day, providing 10% lipid emulsion (100 g fat per liter), infused over 8-12 hours as part of parenteral nutrition, not to exceed 2.5 g fat/kg/day.
None Documented
None Documented
18–24 hours for clearance of infused triglycerides; terminal elimination half-life of soybean oil emulsion particles is approximately 30 minutes for particles <1 µm, but longer for larger particles (up to several hours); clinical context: prolonged half-life in renal/hepatic impairment.
Triglycerides in Liposyn III 10% have a terminal elimination half-life of approximately 0.5 to 1 hour in patients with normal lipid metabolism. In neonates or hepatic impairment, half-life may be prolonged.
Renal: negligible; biliary/fecal: negligible; metabolized in tissues (e.g., muscle, adipose) via beta-oxidation and re-esterification; CO2 production via tricarboxylic acid cycle accounts for majority of elimination.
Lipids are metabolized via hydrolysis by lipoprotein lipase into free fatty acids and glycerol. Free fatty acids undergo beta-oxidation or re-esterification. Elimination of CO2 via lungs; less than 5% excreted renally as glycerol and other metabolites.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion